Cognition Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGTX Nasdaq 2834 www.cogrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cognition Therapeutics, Inc.

Cognition announces outcomes from trial of zervimesine for geographic atrophy - May 9th, 2025 3:31 pm
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - May 9th, 2025 11:30 am
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - May 8th, 2025 11:30 am
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - May 7th, 2025 11:30 am
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - Apr 1st, 2025 11:30 am
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025 - Mar 25th, 2025 11:30 am
Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... - Mar 21st, 2025 7:01 am
Q4 2024 Cognition Therapeutics Inc Earnings Call - Mar 21st, 2025 4:18 am
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - Mar 20th, 2025 11:00 am
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Mar 14th, 2025 12:35 pm
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - Mar 13th, 2025 8:05 pm
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing - Mar 12th, 2025 8:05 pm
Life Sciences Investor Forum Agenda Announced for March 13th - Mar 12th, 2025 5:12 pm
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference - Mar 10th, 2025 11:30 am
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD - Feb 27th, 2025 12:30 pm
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy - Feb 26th, 2025 12:00 pm
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit - Feb 25th, 2025 12:30 pm
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812) - Feb 20th, 2025 12:30 pm
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC - Jan 30th, 2025 12:30 pm
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - Jan 8th, 2025 9:14 pm